PharmaEssentia (6446) Stock Overview
A biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 6/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
6446 Community Fair Values
Create NarrativeSee what 6 others think this stock is worth. Follow their fair value or set your own to get alerts.
100% Patient Improvement in trial puts this $16M Biotech on the radar
Key Takeaways Hoth is a clinical-stage biotech with a diversified pipeline across oncology, neurology, and inflammation. Lead drug HT-001 targets cancer treatment related rashes, a multi-hundred-million-dollar niche where no approved therapies exist.
PharmaEssentia Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$559.00 |
| 52 Week High | NT$717.29 |
| 52 Week Low | NT$396.49 |
| Beta | -0.031 |
| 1 Month Change | 20.45% |
| 3 Month Change | 14.67% |
| 1 Year Change | -2.77% |
| 3 Year Change | 27.25% |
| 5 Year Change | 511.17% |
| Change since IPO | 195.70% |
Recent News & Updates
Recent updates
PharmaEssentia Corporation's (TWSE:6446) 27% Dip In Price Shows Sentiment Is Matching Revenues
Mar 14
There May Be Underlying Issues With The Quality Of PharmaEssentia's (TWSE:6446) Earnings
Mar 05PharmaEssentia Corporation (TWSE:6446) Stock Rockets 25% But Many Are Still Ignoring The Company
Jan 08Does PharmaEssentia (TWSE:6446) Have A Healthy Balance Sheet?
Dec 18Shareholder Returns
| 6446 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 9.2% | 2.2% | 1.2% |
| 1Y | -2.8% | -3.9% | 15.9% |
Return vs Industry: 6446 exceeded the TW Biotechs industry which returned -3.9% over the past year.
Return vs Market: 6446 underperformed the TW Market which returned 15.9% over the past year.
Price Volatility
| 6446 volatility | |
|---|---|
| 6446 Average Weekly Movement | 4.5% |
| Biotechs Industry Average Movement | 6.1% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in TW Market | 8.2% |
| 10% least volatile stocks in TW Market | 2.2% |
Stable Share Price: 6446 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 6446's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | n/a | Ko-Chung Lin | www.pharmaessentia.com |
PharmaEssentia Corporation, a biopharmaceutical company engages in treatment for human diseases in Taiwan and internationally. Its products include Ropeginterferon alfa-2b that is used for the treatment of chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. The company also develops TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint abs for the treatment of solid tumors; P1101 + anti PD-1 for the treatment of hepatocellular carcinoma; and PEG-GCSF for the treatment of neutropenia.
PharmaEssentia Corporation Fundamentals Summary
| 6446 fundamental statistics | |
|---|---|
| Market cap | NT$206.74b |
| Earnings (TTM) | NT$4.05b |
| Revenue (TTM) | NT$12.63b |
Is 6446 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6446 income statement (TTM) | |
|---|---|
| Revenue | NT$12.63b |
| Cost of Revenue | NT$1.50b |
| Gross Profit | NT$11.14b |
| Other Expenses | NT$7.09b |
| Earnings | NT$4.05b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 10.95 |
| Gross Margin | 88.16% |
| Net Profit Margin | 32.06% |
| Debt/Equity Ratio | 0.2% |
How did 6446 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/03 21:32 |
| End of Day Share Price | 2025/10/03 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PharmaEssentia Corporation is covered by 7 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jianzheng Wu | Capital Securities Corporation |
| Wangbin Zhou | Citigroup Inc |
| Hsuan Chen | KGI Securities Co. Ltd. |